another door opens, hopefully a good one…
Researchers found that high expression of the PPP1CA gene is linked to a worse prognosis for patients. They discovered that silencing PPP1CA made cancer cells more susceptible to abiraterone, while overexpressing it had the opposite effect. This suggests that PPP1CA plays a crucial role in protecting cancer cells from abiraterone's effects. The study also identified nodularin-R, a natural product, as a potential inhibitor of PPP1CA. Combining nodularin-R with abiraterone resulted in synergistic inhibition of resistant cancer cells both in vitro and in vivo, indicating that nodularin-R might help overcome abiraterone resistance in CRPC.
New cancer treatment immuno therapy combined with guadecitabine in lung, breast, prostate bowel cancer makes cancer visible to immune sys
Six big things in metastatic prostate cancer
ADT vacation versus Continuous